Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The index has shown a price gain of 1.15% this year. Over the last six months, there has been a stronger performance of -29.55%. The price of CDTX fallen by 16.39% during the last 30 days period. For the last 5-days stocks have improved 25.29%.
Cidara Therapeutics Inc had a pretty Dodgy run when it comes to the market performance. Over the past year, the company’s stock reached a high of $2.10 on 03/22/23, while the lowest price during the same period was $0.59 on 11/17/23.
52-week price history of CDTX Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Cidara Therapeutics Inc’s current trading price is -61.76% away from its 52-week high, while its distance from the 52-week low is 35.43%. The stock’s price range over this timeframe has been between $0.59 and $2.10. The shares of the Healthcare sector company recorded a trading volume of approximately 0.74 million for the day, which was comparatively higher than the average daily volume of 0.72 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Cidara Therapeutics Inc (CDTX) has experienced a quarterly rise of 11.54% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 72.78M and boasts a workforce of 73 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.7322, with a change in price of -0.0054. Similarly, Cidara Therapeutics Inc recorded 579,506 in trading volume during the last 100 days, posting a change of -0.67%.
CDTX’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for CDTX stands at 0.54. Similarly, the long-term debt-to-equity ratio is also 0.41.
CDTX Stock Stochastic Average
Cidara Therapeutics Inc’s raw stochastic average for the past 50 days is currently at 91.33%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 90.61%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 82.51% and 67.80%, respectively.
